Oramed Pharmaceuticals (ORMP) Earnings Date, Estimates & Call Transcripts $2.32 -0.01 (-0.43%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oramed Pharmaceuticals Earnings Summary Upcoming Q1 Earnings DateMay. 8Before Market OpensEstimatedConsensus EPS (Mar. 27) -$0.03 Actual EPS (Mar. 27) $0.01 Beat By $0.04 Oramed Pharmaceuticals released Q4 2024 earnings on March 27, 2025, reporting an EPS of $0.01, which beat the consensus estimate of -$0.03 by $0.04. With a trailing EPS of -$0.21 and a P/E Ratio of 21.09, Oramed Pharmaceuticals' earnings are expected to decrease next year, from ($0.03) to ($0.19) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportORMP Upcoming EarningsOramed Pharmaceuticals' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules. Get Oramed Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataORMP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ORMP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Oramed Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.05-$0.01-$0.03Q2 20252-$0.06-$0.01-$0.04Q3 20252-$0.07-$0.01-$0.04Q4 20252-$0.08-$0.03-$0.06FY 20258($0.26)($0.06)($0.16) Oramed Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/8/2025(Estimated)--------3/27/2025Q4 2024-$0.03$0.01+$0.04$0.01--8/14/2024Q2 2024$0.01$0.22+$0.21$0.22--5/9/2024Q1 2024$0.02$0.04+$0.02$0.04--3/6/2024Q4 2023-$0.12-$0.08+$0.04-$0.49--11/9/2023Q3 2023-$0.09-$0.08+$0.01-$0.08--8/10/2023Q2 2023-$0.11-$0.03+$0.08-$0.03$0.70M$0.67M5/11/2023Q1 2023-$0.23-$0.08+$0.15-$0.08$0.75M$0.67M Oramed Pharmaceuticals Earnings - Frequently Asked Questions When is Oramed Pharmaceuticals's earnings date? Oramed Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based off last year's report dates. Learn more on ORMP's earnings history. Did Oramed Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Oramed Pharmaceuticals (NASDAQ:ORMP) reported $0.01 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.03) by $0.04. Learn more on analysts' earnings estimate vs. ORMP's actual earnings. How much revenue does Oramed Pharmaceuticals generate each year? Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded annual revenue of $1.34 million. How much profit does Oramed Pharmaceuticals generate each year? Oramed Pharmaceuticals (NASDAQ:ORMP) has a recorded net income of $5.53 million. ORMP has generated -$0.21 earnings per share over the last four quarters. What is Oramed Pharmaceuticals's price-to-earnings ratio? Oramed Pharmaceuticals (NASDAQ:ORMP) has a trailing price-to-earnings ratio of 20.73. What is Oramed Pharmaceuticals's EPS forecast for next year? Oramed Pharmaceuticals's earnings are expected to decrease from ($0.03) per share to ($0.19) per share in the next year. More Earnings Resources from MarketBeat Related Companies Allogene Therapeutics Earnings Olema Pharmaceuticals Earnings Entrada Therapeutics Earnings Benitec Biopharma Earnings Cartesian Therapeutics Earnings MBX Biosciences Earnings Septerna Earnings Monte Rosa Therapeutics Earnings ProKidney Earnings Atai Life Sciences Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings Will Make or Break the Stock's Comeback CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of Earnings This page (NASDAQ:ORMP) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORMP Stock Free ORMP Stock Alerts